Mark Emalfarb
Förmögenhet: 5 M $ per 2026-07-31
Förmögenhet: 5 M $ per 2026-07-31
Mark A. Emalfarb is the founder of Dyadic International, Inc., founded in 1979, holding the title of Chief Executive Officer & Director.
Current jobs include Chairman & Chief Executive Officer at Dyadic International (USA), Inc., and Director at Biotechnology Development for Industry in Pharmaceuticals SLU since 2017.
Education includes an undergraduate degree from the University of Iowa, conferred in 1977.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
DYADIC INTERNATIONAL, INC. 13,26 % | 2026-04-24 | 4 832 667 ( 13,26 % ) | 5 M $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| DYADIC INTERNATIONAL, INC. | Grundare | 1979-01-01 |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Verkställande Direktör | 2011-10-05 |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Direktör/Styrelseledamot | 2017-09-13 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Dyadic International, Inc.
Dyadic International, Inc. Medical/Nursing ServicesHealth Services Manufactures genes and other biological products | Health Services |
University of Iowa
University of Iowa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dyadic International (USA), Inc.
Dyadic International (USA), Inc. BiotechnologyHealth Technology Researches and manufactures genes | Health Technology |
Biotechnology Development for Industry in Pharmaceuticals SLU
Biotechnology Development for Industry in Pharmaceuticals SLU Miscellaneous Commercial ServicesCommercial Services Operates as an biotechnology company which produces recombinant proteins | Commercial Services |
Välj din utgåva
All finansiell information anpassad till den nationella nivån